NCT04678882 - Dupilumab in Japanese Patients With Atopic Dermatitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 15, 2021

Primary Completion Date

December 14, 2021

Study Completion Date

October 28, 2023

Conditions

Atopic Dermatitis

Interventions

DRUG

Placebo

Pharmaceutical form: solution for injection Route of administration: subcutaneous (SC)

DRUG

Dupilumab SAR231893

Pharmaceutical form: solution for injection Route of administration: subcutaneous (SC)

Trial Locations (19)

457-8510

Investigational Site Number : 3920011, Nagoya

470-1192

Investigational Site Number : 3920014, Toyoake-shi

811-3217

Investigational Site Number : 3920015, Fukutsu-shi

734-8551

Investigational Site Number : 3920001, Hiroshima

004-0063

Investigational Site Number : 3920013, Sapporo

060-0807

Investigational Site Number : 3920009, Sapporo

653-0836

Investigational Site Number : 3920008, Kobe

658-0082

Investigational Site Number : 3920007, Kobe

252-0392

Investigational Site Number : 3920003, Sagamihara-shi

221-0825

Investigational Site Number : 3920017, Yokohama

225-0015

Investigational Site Number : 3920010, Yokohama

514-0125

Investigational Site Number : 3920006, Tsu

593-8324

Investigational Site Number : 3920020, Sakai-shi

560-0085

Investigational Site Number : 3920019, Toyonaka-shi

360-0018

Investigational Site Number : 3920016, Kumagaya-shi

104-0031

Investigational Site Number : 3920023, Chuo-ku

136-0074

Investigational Site Number : 3920012, Koto-ku

170-0002

Investigational Site Number : 3920022, Toshima-ku

583-8588

Investigational Site Number : 3920021, Habikino-shi